Subscribe to European Biotechnology Magazine’s news feed.
Click on “Follow” and decide if you want to get news from European Biotechnology Magazine via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to European Biotechnology Magazine comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from European Biotechnology Magazine which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: European Biotechnology Magazine
Is this your feed? Claim it!
Stockholm-based Pixelgen Technologies has raised $15.5 million in an oversubscribed Series B round to expand commercialization of its Proxiome platform. The Swedish company is targeting a gap in single-cell analysis: mapping how proteins are organized on the surface of individual cells, rather than simply measuring their abundance.
The post
A Phase III win for Moderna and Merck’s personalized mRNA cancer vaccine has reignited investor enthusiasm for mRNA — and put BioNTech back in the spotlight. But the data are more important than the stock rally: for the first time, a personalized mRNA cancer therapy has produced positive Phase III data in a major indication.
The post
AstraZeneca has discontinued a pivotal Phase III trial of its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC), after an independent committee concluded that the study was unlikely to meet its primary endpoints. The setback comes as the company faces growing pressure to deliver new oncology products.
The post
Germany’s Federal Cartel Office has cleared Merck KGaA’s planned acquisition of U.S. life sciences tools company Bio-Techne, removing one of the key regulatory hurdles to the €9.9 billion deal.
The post
The Copenhagen-based biomanufacturing company is acquiring Genomatica, bringing Geno’s computational biology and industrial biotech expertise into a platform designed to move from pathway discovery to commercial-scale production. The deal highlights a broader shift in industrial biotech: AI is moving beyond molecule design and into the engineering of how biology is manufactur...